pubmed.ncbi.nlm.nih.gov

Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C - PubMed

. 2005 Jul;11(7):750-759.

doi: 10.1002/lt.20453.

Affiliations

Free article

Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C

Russell H Wiesner et al. Liver Transpl. 2005 Jul.

Free article

Abstract

To evaluate the impact of mycophenolate mofetil (MMF) on long-term outcomes of tacrolimus and corticosteroids, we analyzed data reported to the Scientific Registry of Transplant Recipients for 11,670 adult patients (3463 with hepatitis C [HCV]) who underwent primary, single-organ, liver transplantation between 1995 and 2001. Patients who were discharged from the hospital on tacrolimus-based immunosuppression with (n = 4466; n = 1323 HCV) or without MMF (n = 7204; n = 2140 HCV) were included in the analysis. Recipients treated at discharge with MMF, tacrolimus, and corticosteroids had significantly increased patient survival (81.0% vs. 77.0% at 4 years, P < 0.0001) and graft survival (76.4% vs. 72.9%, P < 0.0001), and lower rates of acute rejection (29.0% vs. 33.4%, P < 0.001) as compared to recipients treated at discharge with tacrolimus and corticosteroids alone. A trend toward lower rates of death from infection was observed (6.1% at 4 years for MMF vs. 7.1% at 4 years for tacrolimus and corticosteroids, P = 0.0508), but this result did not reach statistical significance. In multiple regression analyses, MMF triple therapy at discharge was associated with a reduced risk of death (hazard ratio [HR] = 0.77, P < 0.001), graft loss (HR = 0.81, P < 0.001), acute rejection (HR = 0.89, P = 0.002), and death from infectious complications (HR = 0.80, P = 0.007). Outcomes were similar for the cohort with HCV.In conclusion, the addition of MMF at discharge to tacrolimus-based immunosuppression is associated with improved long-term outcomes after liver transplantation in patients with and without HCV.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Department of Health and Human Services. 2003 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1993-2002. Rockville, Md: Health Resources and Services Administration, Office of Special Programs, Division of Transplantation. Richmond, Va: United Network for Organ Sharing. Ann Arbor, Mich: University Renal Research and Education Association.
    1. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7(5): 442-450.
    1. Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami RT, Dyke DB. Immunosuppression: practice and trends. Am J Transplant 2004; 4( suppl 9): 38-53.
    1. Lake JR, Shorr, JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C, and without viral hepatitis. Am J Transplant 2005; 5: 549-557.
    1. Charleton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28(3): 823-830.

Publication types

MeSH terms

Substances

LinkOut - more resources